Australia - English - Department of Health (Therapeutic Goods Administration)

bppr consulting - naloxone hydrochloride dihydrate -

Canada - English - Health Canada

hikma canada limited - naloxone hydrochloride (naloxone hydrochloride dihydrate) - solution - 0.4mg - naloxone hydrochloride (naloxone hydrochloride dihydrate) 0.4mg - opiate antagonists

Australia - English - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - naloxone hydrochloride dihydrate, quantity: 10.9 mg (equivalent: naloxone hydrochloride?, qty 10 mg); oxycodone hydrochloride, quantity: 20 mg - tablet, modified release - excipient ingredients: magnesium stearate; povidone; macrogol 3350; stearyl alcohol; titanium dioxide; lactose monohydrate; purified talc; polyvinyl alcohol; iron oxide red; ethylcellulose - targin modified release tablet is indicated for the management of severe pain where:,- other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and,- the pain is opioid-responsive; and,- requires daily, continuous, long term treatment.,targin modified release tablet is not indicated for use in chronic non-cancer pain other than in exceptional circumstances.,targin modified release tablet is not indicated as an as-needed (prn) analgesia,the naloxone component in a fixed combination with oxycodone is indicated for the therapy and/or prophylaxis of opioid-induced constipation.,targin is indicated as a second line symptomatic treatment of patients with severe to very severe idiopathic restless legs syndrome after failure of dopaminergic therapy.

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - naloxone hydrochloride dihydrate 2,74 mg - eq. naloxone hydrochloride 2,5 mg; oxycodone hydrochloride 5 mg - prolonged-release tablet - 5 mg - 2,5 mg - oxycodone hydrochloride 5 mg; naloxone hydrochloride dihydrate 2.74 mg - oxycodone, combinations

Australia - English - Department of Health (Therapeutic Goods Administration)

southern xp ip pty ltd - naloxone hydrochloride dihydrate, quantity: 440 microgram (equivalent: naloxone hydrochloride?, qty 400 microgram) - injection - excipient ingredients: sodium chloride; water for injections; edetate sodium; hydrochloric acid - naloxone is indicated for the complete or partial reversal of opioid depression, including respiratory depression, induced by natural and synthetic opioids including propoxyphene, methadone, codeine, morphine and heroin, and the mixed opioid agonist-antagonist analgesics such as pentazocine. naloxone is also indicated for the diagnosis of suspected acute opioid overdosage.

Canada - English - Health Canada

auro pharma inc - naloxone hydrochloride - solution - 0.4mg - naloxone hydrochloride 0.4mg - opiate antagonists

Canada - English - Health Canada

eugia pharma inc. - naloxone hydrochloride - solution - 0.4mg - naloxone hydrochloride 0.4mg

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - naloxone hydrochloride dihydrate - solution for injection in pre-filled syringe - naloxone

United States - English - NLM (National Library of Medicine)

actavis pharma, inc. - naloxone hydrochloride (unii: f850569pqr) (naloxone - unii:36b82amq7n) - naloxone hydrochloride nasal spray is indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression. naloxone hydrochloride nasal spray is intended for immediate administration as emergency therapy in settings where opioids may be present. naloxone hydrochloride nasal spray is not a substitute for emergency medical care. naloxone hydrochloride nasal spray is contraindicated in patients known to be hypersensitive to naloxone hydrochloride or to any of the other ingredients. risk summary the limited available data on naloxone use in pregnant women are not sufficient to inform a drug-associated risk. however, there are clinical considerations [see clinical considerations] . in animal reproduction studies, no embryotoxic or teratogenic effects were observed in mice and rats treated with naloxone hydrochloride during the period of organogenesis at doses equivalent to 6-times and 12-times, respectively, a human dose of 8 mg/day (tw

Ireland - English - HPRA (Health Products Regulatory Authority)

b. braun melsungen ag - naloxone hydrochloride - solution for injection/infusion - 400 microgram(s)/millilitre - antidotes; naloxone